Skip to main content

Pfizer’s COVID-19 Pill Has Mixed Results for Healthcare ETFs

Pfizer (NYSE: PFE) is seeking FDA approval for a COVID-19 pill that is highly effective against severe cases of the coronavirus, lifting pharmaceutical sector-related exchange traded funds but dragging on biotech-related ETFs with exposure to some of the company’s biggest competitors. On...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.